GFAP and Alzheimer disease: Herein, we aimed to perform a comprehensive comparison of changes in plasma Aβ42/Aβ40, Aβ42, Aβ40, p-tau181, NfL, and GFAP in the context of established CSF biomarkers from the asymptomatic preclinical stage to symptomatic phases of AD.